USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
In its initial public offering (IPO) on the Hong Kong Stock Exchange, China’s Innovent Biologics has reportedly sold around $421 million worth of shares priced at the top end of estimates, at about $1.78 per share. 25 October 2018
Nine months after announcing that it would stop R&D into new neuroscience drugs, including its work in Alzheimer’s and Parkinson’s diseases, the world’s largest drug company has shown that it is not entirely giving up on this space. 23 October 2018
Chinese biotech Innovent Biologics wants to raise $422 million in an initial public offering (IPO) to take forward its monoclonal antibodies and other biologics in oncology, ophthalmology, autoimmune, and cardiovascular diseases. 16 October 2018
Initial public offerings (IPOs) are often seen as attractive by business owners in the life sciences or biotech field, writes Alan Wovsaniker, a partner with Lowenstein Sandler, in an Expert View column on the topic. 11 October 2018
Sitryx, a new, Oxford, UK-based biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation, today announces it has closed its Series A financing round. 8 October 2018
OxStem, an Oxford University spin-out developing regenerative medicine-based therapies, is launching two subsidiary companies to develop regenerative treatments for diabetes and chronic inflammation and wound healing. 4 October 2018
UK biotechnology companies have already raised more than £1.5 billion ($1.97 billion) in 2018, surpassing the 2017 annual total of £1.2 billion. 28 September 2018
After raising a bumper $96 million through its Nasdaq listing last week, Y-mAbs Therapeutics continued to gain value in its first day of trading, rising 50% to $24 per share. 24 September 2018
San Franciscan microbial genomics specialist uBiome has raised $83 million in a series C financing round directed at funding an expansion into therapeutics. 21 September 2018
A possible $1 billion initial public offering on the Hong Kong Stock Exchange could give the lie to rumors that the spate of bullish biotech listings in China is about to end. 20 September 2018
Texas, USA-based Molecular Templates saw its share surge 54.22% to $6.25 by close of trading on Wednesday after is announced a potentially lucrative deal with Japan’s largest pharma company. 20 September 2018
Swiss drugmaker Vifor Pharma has upped its equity stake in ChemoCentryx, a company with a current focus on late-stage candidates for patients with rare kidney diseases. 18 September 2018
UK biopharma company Arecor has raised £6 million ($7.8 million) from new and existing investors to develop groundbreaking pharmaceutical drugs to transform the treatment of diabetes. 10 September 2018
Oxford University biotech spinout Evox Therapeutics has raised £35.5 million ($45.4 million) in a series B financing round, with new money from Google’s venture capital unit GV, and Cowen Healthcare Investments. 3 September 2018
Before joining Boston University to study biomedical engineering and chemistry, Mass Innovation Labs founder Amrit Chaudhuri was the youngest paid researcher at the MIT-affiliated Whitehead Institute for Biomedical Research, at age 15. 3 September 2018
Boston, USA-based Vertex Pharmaceuticals and the UK’s Genomics have announced a three-year collaboration to use human genetics and machine learning to improve discovery of targets for precision medicines. 30 August 2018
A leading Chinese investment group has taken a stake in Oxford BioDynamics (AIM: OBD), a UK biotech focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. 22 August 2018
Amphion Innovations, a developer of medical, life science, and technology businesses, has announced that 3 million shares in partner company, Motif Bio have been sold directly to an institutional investor at 33.5 pence per share. 21 August 2018
Money flooded into initial public offerings and venture financing for young biotech companies in the first half of 2018, according to a report by Vantage, the editorial arm of the intelligence firm Evaluate. 20 August 2018
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news